Keith Stockerl-Goldstein, M.D.

Honors and Awards

• Phi Beta Kappa, Washington University (1986)
• Alpha Omega Alpha, UCLA School of Medicine (1991)
• Senior Research Award, Multiple Myeloma Research Foundation (1999)
• Faculty Scholar Award, Center For Clinical Immunology at Stanford (1999-2002)
• Divisional Teaching Award, Stanford University (2001)

Professional Education

Graduate & Fellowship Program Affiliations

• Medicine

Web Site Links

• Stanford BMT Web Site

Research Interests

Clinical investigations focus on the use of high dose therapy and bone marrow or peripheral blood progenitor cell transplantation for the treatment of malignant diseases. A major focus is the use of high dose sequential therapy with autologous peripheral blood progenitor cell support followed by idiotype vaccinations for the treatment of multiple myeloma. This study includes efforts to detect minimal residual disease and assess immune response to vaccination. An ongoing trial using non-myeloablative allogeneic transplants for patients with multiple myeloma continues. The use of high dose therapy for the treament of amyloidosis is also being investigated. . Additional research interests include ethical issues associated with high dose therapy, as well as ICU care following transplantation.

Publications

• Allogeneic transplantation for adult patients with acute myeloid leukemia Stockerl-Goldstein, K.E., Blume, K.G.. Thomas’ Hematopoietic Cell Transplantation (Ed 3). 2004: 1025-1039
• A decade of progress in allogeneic hematopoietic cell transplantation: 1990-2000. Stockerl-Goldstein KE, Blume KG. Adv Cancer Res. 2001: 81 1-59
• High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE. Biol Blood Marrow Transplant. 2006; 12 (7): 703-11
• Protective conditioning for acute graft-versus-host disease. Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Hoppe RT, Bloch DA, Blume KG, Negrin RS, Strober S. N Engl J Med. 2005; 353 (13): 1321-31
• Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Cao TM, Shizuru JA, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Stuart MJ, Grumet FC, Negrin RS, Lowsky R. Blood. 2005; 105 (6): 2300-6